CORE--VACCINE AND IMMUNOLOGY

核心——疫苗与免疫学

• 批准号: 6234902
• 负责人: Arye Rubenstein
• 金额: $ 10.35万
• 依托单位: ALBERT EINSTEIN COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-03-01 至 1998-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6234902
• 关键词: AIDS vaccines; HIV envelope protein gp120; antiviral antibody; biomarker; biomedical facility; cellular immunity; cytotoxic T lymphocyte; enzyme linked immunosorbent assay; human immunodeficiency virus 1; humoral immunity; immunoglobulin A; immunoglobulin G; immunologic assay /test; lymphocyte proliferation

The redirection of the thematic areas at the AECOM CFAR to immune-based therapeutic and preventive agendas has mandated in 1990 the conversion of the original hybridoma core into an immunology/vaccine core. This new core standardizes a wide array of immunology markers in the context of antiviral and immune based interventions targeted at manifestation of host defense mechanisms in order to prevent infection or improve outcome. The core will provide access to otherwise unobtainable research capabilities in two major categories critical for the CFAR's progress: (a) Immunological surrogate markers, such as neopterin, Beta2, TNFalpha, sCD8. (b) HIV specific assays targeted to variety of epitopes, but currently focused on gp120 and in the V3 loop primary neutralizing domain (PND) (i) Humoral immune response: serum and secretory IgA (purified at the core) will be assessed for PND reactivity, PND high affinity/avidity cross reactivity; PND and IgG-subclass specific antibodies. (ii) Cellular immunity: Antigen (PND;gp120) driven lymphocyte proliferation, secretion of IL2;IL4;IL10; and specific CTLs of PBMC and sorted cells. This core will be highly interactive with other cores, but more so with the FACS and virology cores. The Core Director will continuously assess the needs for incorporation of new promising immunological assays critical in advancing the common goals of the CFAR and the AECOM-AIDS research agenda. He will be responsible to keep CFAR investigators abreast of new developments in core capabilities and enrich those by interaction with the CFAR committees, the EAC and through visiting scientists/consultants.

将AECOM CFAR的主题领域转向基于免疫的 治疗和预防议程在1990年规定了转换 将最初的杂交瘤核心转化为免疫学/疫苗核心。 这一新的核心标准化了广泛的免疫学标志物 以抗病毒和免疫为基础的干预措施的背景 体现宿主防御机制，以预防感染 或者改善结果。核心将提供对其他方面的访问 在两个主要类别中无法获得的研究能力 CFAR的进展： (A)免疫替代标志物，如新喋呤、贝塔2、肿瘤坏死因子α、 CD8。 (B)针对各种表位的艾滋病毒特异性检测，但目前 聚焦于gp120和在V3环的初级中和结构域(PND) 体液免疫反应：血清和分泌型免疫球蛋白A(在 CORE)将评估PND反应性、PND高亲和力/亲和力 交叉反应；PND和Ig G亚类特异性抗体。 (Ii)细胞免疫：抗原(PND；gp120)驱动的淋巴细胞 IL-2、IL-4、IL-10的增殖和分泌，以及PBMC和 已排序单元格。 该内核将与其他内核高度交互，但与其他内核的互动性更强 FACS和病毒学核心。核心主管将持续评估 纳入新的有希望的免疫学分析方法的必要性 对推进CFAR和AECOM的共同目标至关重要--艾滋病 研究议程。他将负责让CFAR调查人员 跟上核心能力的新发展，并通过以下方式丰富这些发展 与CFAR委员会、东非共同体的互动以及通过访问 科学家/顾问。